Nintedanib, which also inhibits the receptors of VEGF, as well as platelet-derived growth factors (PDGFs) and fibroblast growth factors, showed a trend toward reducing declines in lung function, with fewer acute exacerbations and preserved quality of life [ 4 ].
← all excerpts
Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease.
1
—
—